Also trades as: 0K16.L (LSE) · $vol 0M
EOLS NASDAQ
Evolus, Inc.
1W: -10.4%
1M: -21.2%
3M: +2.1%
YTD: +6.2%
1Y: +16.1%
3Y: -21.4%
5Y: -9.3%
$7.14
-0.55 (-7.15%)
Weekly Expected Move ±6.8%
$6
$7
$7
$8
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-03-23
Earliest Filing
2023-12-20
Latest Filing
partner: 6
customer: 1
supplier: 1
Counterparties (Filed by EOLS)
8 relationshipsCompanies named in EOLS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Symatese Aesthetics S.A.S. | — | partner | Entered into a License, Supply and Distribution Agreement granting Evolus Europe exclusive rights to commercialize and d | 2023-12-20 | View |
| Daewoong Pharmaceuticals Co., Ltd. | — | partner | Partner in a License and Supply Agreement amendment modifying pricing and relinquishing rights to sell in Russia. | 2022-12-13 | View |
| Daewoong Pharmaceuticals Co., Ltd. | — | customer | Paid $25.5 million pursuant to a Confidential Settlement and Release Agreement. | 2021-04-26 | View |
| SVB Leerink LLC | — | partner | Sales agent for the open market sales agreement of ATM Shares. | 2021-03-26 | View |
| Daewoong Pharmaceuticals Co., Ltd. | — | supplier | Exclusive manufacturer and supplier of Jeuveau®; entered into settlement, conversion, and supply agreement amendments wi | 2021-03-23 | View |
| Medytox, Inc. | — | partner | Plaintiff in ITC and litigation actions; party to settlement and license agreements with Evolus, Inc. | 2021-03-23 | View |
| Allergan, Inc. | — | partner | Plaintiff in ITC and litigation actions; party to settlement and license agreements with Evolus, Inc. | 2021-03-23 | View |
| Allergan Limited | — | partner | Plaintiff in ITC and litigation actions; party to settlement and license agreements with Evolus, Inc. | 2021-03-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-08-04 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-07-08 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-06-12 | Shareholder Vote | View | |
| 2026-05-04 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-13 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-03-03 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Creation of | Agreement | View |
| 2026-01-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-08 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-06-06 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-27 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-05 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
| 2025-03-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-21 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-07-01 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR